Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.

Autor: Friedman JS; Departments of Neurology, Neurosurgery, and Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Durham BH; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Pathology, Mayo Clinic, Rochester, Minnesota, USA.; Department of Molecular Pharmacology, Sloan Kettering Institute, New York, New York, USA., Reiner AS; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Yabe M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Petrova-Drus K; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Dogan A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Pulitzer M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Busam KJ; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Francis JH; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Rampal RK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Ulaner GA; Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, California, USA.; Molecular Imaging and Therapy, University of Southern California, Los Angeles, California, USA., Reddy R; Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, California, USA.; Molecular Imaging and Therapy, University of Southern California, Los Angeles, California, USA.; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Yeh R; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Hatzoglou V; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Lacouture ME; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Rotemberg V; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Mazor RD; Clinic of Histiocytic Neoplasms, Institute of Hematology, Assuta Medical Center, Tel-Aviv, Israel., Hershkovitz-Rokah O; Department of Molecular Biology, Faculty of Natural Sciences, Ariel University, Ariel, Israel.; Translational Research Lab, Assuta Medical Centers, Tel-Aviv, Israel., Shpilberg O; Clinic of Histiocytic Neoplasms, Institute of Hematology, Assuta Medical Center, Tel-Aviv, Israel.; Adelson School of Medicine, Ariel University, Ariel, Israel., Goyal G; Department of Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.; Rare Histiocytic Disorders Steering Committee of the Histiocyte Society., Go RS; Rare Histiocytic Disorders Steering Committee of the Histiocyte Society.; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA., Abeykoon JP; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA., Rech K; Department of Pathology, Mayo Clinic, Rochester, Minnesota, USA.; Rare Histiocytic Disorders Steering Committee of the Histiocyte Society., Morlote D; Department of Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA., Fidai S; Department of Pathology, John H. Stroger Hospital of Cook County, Chicago, Illinois, USA., Gannamani V; Department of Pathology, John H. Stroger Hospital of Cook County, Chicago, Illinois, USA., Zia M; Department of Pathology, John H. Stroger Hospital of Cook County, Chicago, Illinois, USA., Abdel-Wahab O; Department of Molecular Pharmacology, Sloan Kettering Institute, New York, New York, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Panageas KS; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Rosenblum MK; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Diamond EL; Rare Histiocytic Disorders Steering Committee of the Histiocyte Society.; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Jul; Vol. 205 (1), pp. 127-137. Date of Electronic Publication: 2024 Apr 12.

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Autor: Dreyling, M., Campo, E., Hermine, O., Jerkeman, M., Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., Ladetto, M.

Publikováno v: In Annals of Oncology July 2017 28 Supplement 4:iv62-iv71

Novel pyrrolidine-aminophenyl-1,4-naphthoquinones: structure-related mechanisms of leukemia cell death.

Autor: Hallak M; Institute of Hematology, Soroka University Medical Center, Beer Sheva, Israel.; Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, P.O. Box 653, 8410501, Beer Sheva, Israel., Danilenko M; Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, P.O. Box 653, 8410501, Beer Sheva, Israel. misha@bgu.ac.il., Win T; Department of Chemistry, Ben-Gurion University of the Negev, Beer Sheva, Israel., Bittner S; Department of Chemistry, Ben-Gurion University of the Negev, Beer Sheva, Israel., Granot Y; Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel., Shpilberg O; Assuta Medical Center, Tel-Aviv, Israel., Levi I; Institute of Hematology, Soroka University Medical Center, Beer Sheva, Israel.; Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, P.O. Box 653, 8410501, Beer Sheva, Israel., Nathan I; Institute of Hematology, Soroka University Medical Center, Beer Sheva, Israel.; Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, P.O. Box 653, 8410501, Beer Sheva, Israel.

Publikováno v: Molecular and cellular biochemistry [Mol Cell Biochem] 2023 Feb; Vol. 478 (2), pp. 393-406. Date of Electronic Publication: 2022 Jul 14.

Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms.

Autor: Durham BH; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Hershkovitz-Rokah O; Department of Molecular Biology, Faculty of Natural Sciences, Ariel University, Ariel, Israel.; Translational Research Lab, Assuta Medical Centers, Tel Aviv, Israel., Abdel-Wahab O; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY., Yabe M; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Chung YR; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY., Itchaki G; Department of Hematology, Rabin Medical Center, Petah Tikva, Israel., Ben-Sasson M; The Institute for Pain Medicine, Rambam Medical Center, Haifa, Israel.; The Rappaport School of Medicine, Technion, Haifa, Israel.; Meuhedet Health Maintenance Organization, Zikhron Ya'akov, Israel., Asher-Guz VA; Department of Molecular Biology, Faculty of Natural Sciences, Ariel University, Ariel, Israel.; Translational Research Lab, Assuta Medical Centers, Tel Aviv, Israel., Groshar D; Department of Imaging, Assuta Medical Center, Tel Aviv, Israel., Doe-Tetteh SA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY., Alano T; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, NY., Solit DB; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY., Shpilberg O; Translational Research Lab, Assuta Medical Centers, Tel Aviv, Israel.; Clinic of Histiocytic Neoplasms, Institute of Hematology, Assuta Medical Center, Tel Aviv, Israel.; The Adelson School of Medicine, Ariel University, Ariel, Israel., Diamond EL; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY., Mazor RD; Clinic of Histiocytic Neoplasms, Institute of Hematology, Assuta Medical Center, Tel Aviv, Israel.

Publikováno v: Blood advances [Blood Adv] 2023 Dec 12; Vol. 7 (23), pp. 7319-7328.

Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study.

Autor: Thurner L; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany., Ziepert M; Institute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Germany., Berdel C; Department of Radiotherapy and Radiation Oncology, Saarland University Medical School, Homburg/Saar, Germany., Schmidt C; Department of Medicine III, University Hospital, Munich, Germany., Borchmann P; Department of Hematology and Oncology, University Hospital of Cologne, Germany., Kaddu-Mulindwa D; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany., Viardot A; Department of Internal Medicine III, University Hospital Ulm, Germany., Witzens-Harig M; Department of Internal Medicine V, University of Heidelberg, Germany., Dierlamm J; Department of Internal Medicine II, University Hospital Eppendorf, Hamburg, Germany., Haenel M; Department of Internal Medicine III, Küchwald Hospital Chemnitz, Germany., Metzner B; Department of Hematology and Oncology, University Clinic, Klinikum Oldenburg, Germany., Wulf G; Department of Hematology and Oncology, Georg August University of Goettingen, Germany., Lengfelder E; Department of Internal Medicine III, University Hospital Mannheim, Germany., Keller UB; Department of Internal Medicine III, Klinikum rechts der Isar der TU München, Munich, Germany., Frickhofen N; Department of Internal Medicine III, Helios Dr. Horst-Schmidt-Kliniken, Wiesbaden, Germany., Nickelsen M; Oncology Lerchenfeld, Hamburg, Germany., Gaska T; Department of Hematology and Oncology, Brüderkrankenhaus St. Josef, Paderborn, Germany., Griesinger F; Department of Internal Oncology, Pius-Hospital, Oldenburg, Germany., Mahlberg R; Department of Internal Medicine I, Klinikum Mutterhaus der Borromaerinnen, Trier, Germany., Marks R; Department of Hematology and Oncology, University Medical Center, Freiburg, Germany., Shpilberg O; Department of Hematology, Rabin Medical Center, Beilinson Hospital, Petah-Tiqwa, Israel., Lindemann HW; Department of Hematology and Internal Oncology, St.-Josefs-Hospital, Hagen, Germany., Soekler M; Department of Internal Medicine II, University Hospital Tuebingen, Germany., Fischer von Weikersthal L; Medical Service Center, Klinikum St. Marien, Amberg, Germany., Kiehl M; Department of Internal Medicine, Klinikum Frankfurt (Oder), Germany., Roemer E; Department of Gastroenterology, Nephrology, Diabeteology, Hematoloy, Internal Oncology and Internal Intensive Medical Care, Klinikum Idar-Oberstein, Germany., Bentz M; Department of Hematology and Oncology, Städtisches Klinikum, Karlsruhe, Germany., Krammer-Steiner B; Department of Internal Medicine, Klinikum Rostock Südstadt, Germany., Trappe R; Department of Internal Medicine II, Evang. Diakonie-Krankenhaus gGmbH, Bremen, Germany., de Nully Brown P; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Federico M; CHIMOMO Department, University of Modena and Reggio Emilia, Italy., Merli F; Hematology Azienda USL-IRCCS of Reggio Emilia, Italy., Engelhard M; Department of Radiotherapy, University Hospital Essen, Germany., Glass B; Department of Hematology and Stem Cell Transplantation, Helios Klinikum Berlin-Buch, Germany., Schmitz N; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Germany., Truemper L; Department of Hematology and Oncology, Georg August University of Goettingen, Germany., Bewarder M; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany., Hartmann F; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany., Murawski N; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany., Stilgenbauer S; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany., Rosenwald A; Institute of Pathology, University of Wuerzburg, and Comprehensive Cancer Center Mainfranken, Germany., Altmann B; Institute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Germany., Schmidberger H; Department of Radiooncology and Radiotherapy, University Medical Center, Mainz, Germany., Fleckenstein J; Department of Radiotherapy and Radiation Oncology, Saarland University Medical School, Homburg/Saar, Germany., Loeffler M; Institute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Germany., Poeschel V; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany., Held G; Department of Internal Medicine 1, Westpfalz-Klinikum, Kaiserslautern, Germany.

Publikováno v: HemaSphere [Hemasphere] 2023 Jul 05; Vol. 7 (7), pp. e904. Date of Electronic Publication: 2023 Jul 05 (Print Publication: 2023).